Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: Extended analysis from a European multidatabase cohort study

BMJ Open Diabetes Research and Care

Volumn 6, Issue 1, 2018, Pages

  Strongman, Helen ^a   Christopher, Solomon ^b   Majak, Maila ^b   Williams, Rachael ^a   Bahmanyar, Shahram ^c   Linder, Marie ^c   Heintjes, Edith M ^d   Bennett, Dimitri ^e   Korhonen, Pasi ^b,f   Hoti, Fabian ^f  

^a Clinical Practice Research Datalink   (United Kingdom)

^b EPID Research   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^e TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^f EPID Research   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE SPECIFIC MORTALITY RATE; DIABETIC MACULOPATHY; DIABETIC RETINOPATHY; DISEASE EXACERBATION; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETINA MACULOPATHY; TREATMENT DURATION;

EID: 85041401554     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2017-000481     Document Type: Article

References (17)

1. Leal J, Gray AM, Clarke PM. Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J 2009;30:834-9.
2. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-31.
3. Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001;322:1389-93.
4. Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: Retrospective cohort study using datasets from four European countries. BMJ 2016;354:i3903.
5. Strongman H, Korhonen P, Williams R, et al. Pioglitazone and risk of mortality in patients with type 2 diabetes: Results from a European multidatabase cohort study. BMJ Open Diabetes Res Care 2017;5:e000364.
6. Yang J, Vallarino C, Bron M, et al. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: An expanded analysis from a retrospective cohort study. Curr Med Res Opin 2014;30:2223-31.
7. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ 2016;354:i3477.
8. Liao HW, Saver JL, Wu YL, et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-Analysis. BMJ Open 2017;7:e013927.
9. Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. Arch Toxicol 2016;90:1861-81.
10. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-81.
11. Brown AF, Ettner SL, Piette J, et al. Socioeconomic position and health among persons with diabetes mellitus: A conceptual framework and review of the literature. Epidemiol Rev 2004;26:63-77.
12. World Health Organisation. International statistical classification of diseases and related health problems - 10th revision. 5th edn, 2016. http://apps.who.int/classifications/icd10/browse/Content/statichtml/ICD10Volume2-en-2016.pdf?ua=1&ua=1 (cited 13 Nov 2017).
13. Brooke HL, Talback M, Hornblad J, et al. The Swedish cause of death register. Eur J Epidemiol 2017;32:765-73.
14. Office for National Statistics. Mortality statitistics in England and Wales QMI [Internet], 2017. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/qmis/mortalitystatisticsinenglandandwalesqmi (cited 2017 Nov 13).
15. Official Statistics of Finland (OSF). Causes of death. ISSN=1799- 5078. http://www.stat.fi/til/ksyyt/laa-en.html.
16. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.
17. Erdmann E, Harding S, Lam H, et al. Ten-year observational followup of PROactive: A randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab 2016;18:266-73.